Boehringer Ingelheim International Gmbh

Aerie Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Frank Wu

Michael Robert Turner

John David Ginn

Anthony S Prokopowicz

Sabine K Schlyer

Di Wu

Robert Sibley

Roger John Snow

Ronald John Sorcek

Daniel Richard Marshall

Weimin Liu

Todd Bosanac

Thomas Martin Kirrane, Jr

Erick Richard Roush Young

Erick Richard Young

Cheng-Kon Shih

Eugene Richard Hickey

Eugene R Hickey

Georg Dahmann

Tina Marie Morwick

Xiang Li

Xin Guo

Wang Mao

Jennifer A Kowalski

Stephen James Boyer

Thomas Martin Kirrane

Anthony S Iii Prokopowicz

Sabine Schyler

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

Rho kinase inhibitors

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rto R, A, B, X, and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

CXCR3 receptor antagonists

Isoquinolinone Rho kinase inhibitors

Mineralocorticoid receptor antagonists, of which the following is exemplary. 

Mineralocorticoid receptor antagonists

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rto R, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rto R, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma.

Growing community of inventors

Ridgefield, CT, United States of America

Frank Wu